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ABSTRACT Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects
children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCGureC::hly
(strain VPM1002) is in advanced clinical trials and shows promise for improved vaccine safety but little change in efficacy in ani-
mal models. A second-generation recombinant BCG vaccine with an additional deletion of the nuoG gene (BCGureC::hly
nuoG) shows improved efficacy in a mouse model compared to that of VPM1002. BCGwas first used in humans in 1921 and,
like Sleeping Beauty pricked by the spinning wheel, we have slept for 100 years, showing a reluctance to invest in clinical devel-
opment or in biomanufacturing capacity for TB vaccines. The advance of recombinant BCGs should awaken us from our sleep
and call us to invest in new-generation TB vaccines and to protect the biomanufacture of our current BCG vaccine.
BACKGROUND
Nearly 2 million people die each year of tuberculosis (TB), andan estimated one-third of the world’s population is in-
fected with Mycobacterium tuberculosis (1). In 2015, TB was
reported as the leading cause of death due to a single infectious
disease (2). Improved diagnostics and shorter, less toxic drug
treatments would help to reduce the global burden of disease,
but a significant impact on the rate of TB disease can only be
made with a more effective vaccine (http://www.who.int/tb/
post2015_strategy/en/) (3).
Bacille Calmette-Guérin (BCG) is the only currently licensed
vaccine for the prevention of TB. BCG is a live, attenuated strain of
Mycobacterium bovis that was attenuated through passage of the
organism in culture more than 230 times. Seed stock of BCG was
distributed to other manufacturers, and the process of attenuation
continued, resulting in more than 16 (4) distinct strains of BCG
vaccine worldwide. BCG is one of the most widely used vaccines in
the world, but its efficacy is highly variable. In a recent meta-
analysis of the literature, it was shown that the efficacy of BCG is
lower in those with previous exposure to environmental myco-
bacteria or to M. tuberculosis itself (as assessed by reactivity to the
tuberculin skin test) (5). The efficacy of BCG in countries where
TB is endemic is therefore highest in unexposed infants and lowest
in adults, with an average efficacy of 50% in children and typically
no efficacy in adults.
The importance of the Th1 pathway in protective immunity
has been confirmed through multiple observations from human
genetic studies and murine M. tuberculosis challenge experiments.
In South African infants, the BCG-specific gamma interferon
(IFN-) enzyme-linked immunosorbent spot assay (ELISPOT)
response was associated with reduced TB disease risk over the
following 1 to 3 years of life (6). This immune response was pre-
dominantly a CD4 polyfunctional response, with little detection
of antigen-specific CD8 T cells at the time point tested (4 to
6 months of age) (6).
New TB vaccines seek to improve protection against TB either
by increasing the magnitude of the CD4 T cell response induced by
BCG or by broadening the immune response, for example,
through the induction of a CD8 T cell response. Strategies for
improved protection include whole-mycobacterial-cell-derived
vaccines, virus-vectored subunit vaccines, and adjuvanted protein
subunit vaccines (7). The subunit vaccines are typically given after
BCG immunization to boost the immune response primed by
BCG, whereas whole-mycobacterial vaccines can either be used
as BCG booster vaccines or as a replacement for BCG. The current
BCG vaccine is thus able to confer protection, but room for im-
proved protection through boosting or broadening of immunity
exists.
RECOMBINANT BCG VACCINES
BCG ureC::hly (strain VPM1002) is a recombinant BCG strain
that has been modified by the insertion of listeriolysin and the
deletion of urease (8). These modifications aim to enhance both
the immunogenicity and the safety of the parental BCG vaccine
strain. Listeriolysin is thought to perforate the phagolysosome,
enabling leakage of mycobacterial antigen from VPM1002 into
the cytosol and, thus, facilitating cross-presentation and the en-
hancement of a CD8 T cell response (8). VPM1002 enhances in-
flammasome activation and autophagy in C57BL/6 mice (9);
mouse studies also showed an association of central memory CD4
T cells and T follicular helper cells with the increased protection
(10). These immune responses are broader than those induced by
the parental BCG strain, where a CD4 Th1 response dominates.
In early-phase clinical trials, the CD4 and CD8 antigen-specific
responses to VPM1002 did not differ from those induced by BCG,
although there was early enhancement of purified protein deriva-
tive (PPD)-specific antibodies (11).
Due to an enhanced safety profile in preclinical models,
VPM1002 is being assessed as a BCG replacement vaccine for
HIV-exposed infants. The risk of disseminated disease due to
uncontrolled replication of the current BCG vaccine is higher
in HIV-exposed infants, and therefore, BCG is not recom-
mended in this population. Phase II trials are ongoing in South
Africa and are due to start in India soon, with market entry
expected within 5 years (http://www.tbvi.eu/wp-content
/uploads/2016/02/Grode_SII-VPM-Status-on-TB-vaccine
-150318.pdf). Phase III trials for prevention of the recurrence of
TB disease in those previously treated for TB are also expected to
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commence in India within the next few years (http:
//indianexpress.com/article/explained/a-new-tb-vaccine-is-in
-the-works-and-heres-why-india-is-excited/). If these clinical
trials prove VPM1002 to be safe, even if not more effective against
clinical disease, VPM1002 will be the first new TB vaccine to enter
the market since 1921, when BCG was first used in humans.
Research with recombinant BCG strains continues (reviewed
in reference 12). Gengenbacher et al. report that the inflam-
masome activation and autophagy induced by VPM1002 can be
further enhanced through the deletion of nuoG (BCG ureC::hly
nuoG) (13). The nuoG gene encodes NADH-quinone oxi-
doreductase and is involved in mycobacterial respiration. Dele-
tion of this gene leads to enhanced apoptosis of the host cell during
mycobacterial infection (14, 15). Gengenbacher et al. show that
the protective efficacy of VPM1002 in the mouse model is further
improved by the deletion of nuoG (13).
IMPACT OF A NEW RECOMBINANT BCG VACCINE ON THE
DEVELOPMENT OF VPM1002
If BCG ureC::hly nuoG is more effective than VPM1002, what
are the implications for the current clinical development of
VPM1002? BCG was first used as a human vaccine in 1921 and,
like Sleeping Beauty pricked by the spinning wheel, we have slum-
bered for 100 years, depending on BCG alone for protection. The
high risk of failure of TB vaccine candidates in costly, late-phase
clinical trials and the low commercial value of a TB vaccine to
industry are blamed in part for the sluggish pace of TB vaccine
development (16). VPM1002 may be the first new-generation TB
vaccine to enter the market as a safer alternative to the BCG vac-
cine in HIV-exposed infants. After the introduction of VPM1002,
we should not sink back into our sleep for another 100 years
but should capitalize on our expertise, iteratively improving
VPM1002 and our other vaccine candidates, in addition to gener-
ating novel vaccine platforms. Through the clinical development
of VPM1002 and other vaccine candidates, such as MVA85A, we
have advanced our understanding of immune correlates and built
capacity for clinical testing and biomanufacturing that will greatly
accelerate the development process for 2nd-, 3rd-, and 4th-
generation TB vaccine candidates.
BCG ureC::hly nuoG is our wake-up call, which has shown
us that there is potential for further improvement on the protec-
tion induced by BCG and VPM1002. We should respond to this
call for action with increased energy and investment in TB vaccine
development.
IMPACT OF A NEW RECOMBINANT BCG VACCINE ON THE
CURRENTLY USED BCG
What are the implications for the current BCG vaccine if
VPM1002 enters the market in the next 5 to 10 years? We should
not forget that BCG is an effective vaccine for the prevention of TB
disease for many individuals. Enthusiasm for new vaccines must
not overshadow support for an existing, effective vaccine. Glob-
ally, there have been shortages in the BCG vaccine supply since
2013, and the situation appears to be worsening, with a shortage of
8 million doses in 2014 and 17 million doses in 2015 (17). The
BCG shortage has highlighted the shocking fragility of the global
manufacturing capacity for the only available vaccine against TB,
the world’s leading cause of death due to a single infectious agent.
It is not clear who should take responsibility for rebuilding man-
ufacturing capacity and protecting our BCG supplies for the fu-
ture. We are many decades away from seeing a recombinant BCG
vaccine replace the current BCG vaccine for global use. Perhaps
we should be asking ourselves if, while building capacity for the
manufacture of recombinant BCGs, we also have a moral respon-
sibility to support and rebuild capacity for the manufacture of the
current BCG vaccine.
SUMMARY
In the next 5 to 10 years, the recombinant BCG vaccine BCG
ureC::hly (VPM1002) may be the first TB vaccine to enter the
market since BCG was first used in 1921. Like Sleeping Beauty, we
have slumbered for 100 years with the current BCG vaccine, show-
ing a reluctance to invest in clinical development and neglecting
to secure existing biomanufacturing capacity. BCG ureC::hly
nuoG is our wake-up call, showing us that we can and should
make better vaccines with continued effort. TB vaccine develop-
ment requires scientists to be awake and alert so that the introduc-
tion of the first recombinant BCG vaccine accelerates and does not
stop the development of 2nd- and 3rd-generation vaccine candi-
dates. Only through protection of our current BCG vaccine stocks
and continued investment in preclinical and clinical development
can we hope to reduce the global burden of TB disease.
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